These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36739697)

  • 21. Rho kinase inhibition by fasudil attenuates cyclosporine-induced kidney injury.
    Park JW; Park CH; Kim IJ; Bae EH; Ma SK; Lee JU; Kim SW
    J Pharmacol Exp Ther; 2011 Jul; 338(1):271-9. PubMed ID: 21474569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rho-Associated Protein Kinase-1 Mediates the Regulation of Inflammatory Markers in Diabetic Retina and in Retinal Müller Cells.
    Mohammad G; AlSharif HM; Siddiquei MM; Ahmad A; Alam K; Abu El-Asrar AM
    Ann Clin Lab Sci; 2018 Mar; 48(2):137-145. PubMed ID: 29678838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.
    Kikuchi Y; Yamada M; Imakiire T; Kushiyama T; Higashi K; Hyodo N; Yamamoto K; Oda T; Suzuki S; Miura S
    J Endocrinol; 2007 Mar; 192(3):595-603. PubMed ID: 17332527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
    Chen XY; Dun JN; Miao QF; Zhang YJ
    Pharmacology; 2009; 83(2):67-79. PubMed ID: 19052484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Rho Kinase Inhibition in the Protective Effect of Fasudil and Simvastatin Against 3-Nitropropionic Acid-Induced Striatal Neurodegeneration and Mitochondrial Dysfunction in Rats.
    Ahmed LA; Darwish HA; Abdelsalam RM; Amin HA
    Mol Neurobiol; 2016 Aug; 53(6):3927-3938. PubMed ID: 26169112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.
    Arita R; Hata Y; Nakao S; Kita T; Miura M; Kawahara S; Zandi S; Almulki L; Tayyari F; Shimokawa H; Hafezi-Moghadam A; Ishibashi T
    Diabetes; 2009 Jan; 58(1):215-26. PubMed ID: 18840783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure.
    Komers R; Oyama TT; Beard DR; Tikellis C; Xu B; Lotspeich DF; Anderson S
    Kidney Int; 2011 Feb; 79(4):432-42. PubMed ID: 20962741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuation of Diabetic Nephropathy in Diabetic Mice by Fasudil through Regulation of Macrophage Polarization.
    Xie F; Lei J; Ran M; Li Y; Deng L; Feng J; Zhong Y; Li J
    J Diabetes Res; 2020; 2020():4126913. PubMed ID: 32685556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Rho-kinase inhibitor, fasudil, attenuates progressive glomerulosclerosis induced by daunorubicin in rats.
    Deng B; Yang X; Zhu Z; Zhang C
    J Huazhong Univ Sci Technolog Med Sci; 2009 Dec; 29(6):720-4. PubMed ID: 20037814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signaling through Rho GTPase pathway as viable drug target.
    Lu Q; Longo FM; Zhou H; Massa SM; Chen YH
    Curr Med Chem; 2009; 16(11):1355-65. PubMed ID: 19355891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rho kinase inhibition in diabetic kidney disease.
    Komers R
    Br J Clin Pharmacol; 2013 Oct; 76(4):551-9. PubMed ID: 23802580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation.
    Pearson JT; Jenkins MJ; Edgley AJ; Sonobe T; Joshi M; Waddingham MT; Fujii Y; Schwenke DO; Tsuchimochi H; Yoshimoto M; Umetani K; Kelly DJ; Shirai M
    Cardiovasc Diabetol; 2013 Aug; 12():111. PubMed ID: 24059472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo.
    Deng L; Li G; Li R; Liu Q; He Q; Zhang J
    Cancer Biol Ther; 2010 Jun; 9(11):875-84. PubMed ID: 20364104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fasudil, an inhibitor of Rho-associated coiled-coil kinase, improves cognitive impairments induced by smoke exposure.
    Xueyang D; Zhanqiang M; Chunhua M; Kun H
    Oncotarget; 2016 Nov; 7(48):78764-78772. PubMed ID: 27791202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of favorable effects of Rho kinase inhibition on myocardial remodeling and systolic function after experimental myocardial infarction in the rat.
    Mera C; Godoy I; Ramírez R; Moya J; Ocaranza MP; Jalil JE
    Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):4-20. PubMed ID: 26490279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fasudil alleviates hepatic fibrosis in type 1 diabetic rats: involvement of the inflammation and RhoA/ROCK pathway.
    Xie Y; Song T; Huo M; Zhang Y; Zhang YY; Ma ZH; Wang N; Zhang JP; Chu L
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5665-5677. PubMed ID: 30229844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyl fasudil, an inhibitor of Rho signaling, improves erectile function in diabetic rats: a role for neuronal ROCK.
    Sezen SF; Lagoda G; Musicki B; Burnett AL
    J Sex Med; 2014 Sep; 11(9):2164-71. PubMed ID: 24919622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats.
    Nishikimi T; Koshikawa S; Ishikawa Y; Akimoto K; Inaba C; Ishimura K; Ono H; Matsuoka H
    J Hypertens; 2007 May; 25(5):1053-63. PubMed ID: 17414670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction.
    Baba I; Egi Y; Utsumi H; Kakimoto T; Suzuki K
    Mol Med Rep; 2015 Dec; 12(6):8010-20. PubMed ID: 26498136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.
    Shi J; Wei L
    J Cardiovasc Pharmacol; 2013 Oct; 62(4):341-54. PubMed ID: 23921309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.